GLP1's Weekly Pills Pens and Progress 15

Posted on November 13, 2026 by Sally-Anne Turner

If you take GLP-1s in the UK, you may have woken up this morning to alarming news from the US about a nationwide recall of certain weight-loss injections and GLP-1 medicines. Does this mean all GLP-1s are now unsafe?

Fret not! It has very little to do with the medications themselves. So, what does this mean?

At the Bodyline Clinic, we aim to keep all of our patients and readers up to date with the world of everything weight loss-related. Here, in GLP-1s Weekly Pills Pens and Progress 15, we’ll look at what this recall means and fill you in on other GLP-1-related news this week.

FDA Recall Worries

Starting with the big one, there has been a nationwide recall for specific compounded tirzepatide injections. These were supplied by Apothecary Pharma, and the recall was linked to concerns that their sterility could not be assured. So, it is not a recall of all brands of Mounjaro or Wegovy; rather, it is concerns linked to products prepped by this company.

The impacted tirzepatide contains 19mg/mL and comes in 4 mL multidose vials. This recall covers 22 lots, with beyond-use dates that range from the 7th of October to the 26th of November 2026. A separate medication, an NAD+ injection was also included, highlighting that this was not an issue solely linked to just GLP-1’s.

The recall falls into the “Class II” recall category, meaning using the medication could cause “temporary or medically reversible adverse health consequences.” The lack of sterility assurance means that manufacturing controls cannot reliably establish that the injections are free from contamination. This does not mean that every vial was contaminated.

Indeed, the FDA inspected Apothecary Pharma in May 2025 and issued a warning letter the following December. Why? The investigators noted serious deficiencies in sterile manufacturing practice, as well as issues with labelling and regulatory compliance.

What should be done? People taking GLP-1s in the US should look at their medication’s manufacturer, strength, vial size and lot number against the recall information. Then, they should contact their dispensing pharmacist or prescriber. If you are in the UK, unless you have been shipping your tirzepatide products from the US, your Mounjaro UK is likely safe!

See the FDA recall information here— https://www.accessdata.fda.gov/scripts/ires/?Event=99952

GLP-1 Medicines and Blood Clot Risk

OK, so we don’t mean to go on about how GLP-1’s can help with other areas of health beyond weight loss. But it seems that this is an area that is being noted in the research.

GLP-1 receptor agonists may be associated with fewer blood clots in people who have both type-2 diabetes and atrial fibrillation or an atrial flutter. Indeed, research from Medscape noted that starting a GLP-1 medicine is linked to a 21% lower one-year risk of venous thromboembolism compared with starting a DPP-4 inhibitor, another class of diabetes medication. You should note that this is a relative comparison between treatment groups, rather than a reduction of 21 percentage points.

A quick rundown first. Venous thromboembolism includes deep vein thrombosis and pulmonary embolism. The research addresses a group who are vulnerable: atrial fibrillation is linked to clotting complications, and diabetes can add risk via inflammation as well as changes in the body’s ability to break down clots.

Published in Diabetes, Obesity and Metabolism, the study analysed existing electronic health records from the TriNetX network. This looked at 167 healthcare organisations between January 2018 and December 2024. Participants were adults who were diagnosed with type 2 diabetes and a recorded diagnosis of atrial fibrillation or flutter during the year before treatment began. The research team then used the propensity score to make the treatment groups more comparable.

The only issue is this: this study was observational, and the association cannot be used to state that GLP-1’s directly prevent clots. There may be other factors. As always, this highlights an area worth investigating and does not suggest that this will be a new area for prescribing. Randomised trials will likely be able to find if this offers protective treatments for people in this group.

GLP-1 Medications and Complications after Surgery

Now, onto GLP-1’s and surgery.

GLP-1’s were linked to fewer cardiovascular complications and infections after elective surgery in a large observational study. This was presented at the ANESTHESIOLOGY 2026 annual meeting. Researchers at UTHealth Houston examined records from 2,028,601 US adults, including 145,610 people taking GLP-1 medications.

The participants underwent elective procedures that lasted for longer than one hour and remained in the hospital for a minimum of 24 hours afterwards. The records covered January 2016 to December 2024 and came from Epic Cosmos. That is a database that draws information from 1,700 hospitals and 40,000 clinics.

After matching GLP-1 users with similar patients who were not taking these medicines, the research team found 11% lower odds of cardiovascular complications. These included heart attacks, strokes, heart injury or death. The GLP-1 group were also linked with 8% lower odds of postoperative infections. Those included surgical site infections, urinary tract infections, pneumonia and sepsis.

Why was this the case? Theories include:

  1. GLP-1’s improving blood glucose control
  2. Lower weight complications
  3. Lower blood pressure
  4. Potentially reducing inflammation

Indeed, blood glucose control may also help the body to resist infection. Of course, these are theories and have not been determined in the study. Also, as this was an analysis, it cannot establish whether or when patients stopped their GLP-1 treatment before surgery.

More research is needed. And as mentioned in another one of our GLP-1 Weekly pieces, there are guides on when a person should stop taking GLP-1’s if they are about to undertake surgery due to risk of vomiting. So, an assessment of whether those guidelines were followed would be an interesting note. Also, this study does not mention which GLP-1s or weight-loss medication was identified, so we cannot say whether it was Wegovy or Mounjaro.

The Bodyline Clinic and What We Offer

We know that for many, the idea of reading news relating to GLP-1s can seem, well, tedious. For us, it is the highlight of our week. Why? It allows us to explain to you what is happening in this area, helping you to determine if what we can offer (GLP-1’s, weight loss treatments and appetite suppressants) is right for you.

Our team at the Bodyline Clinic will always be clear with you when you come to us for weight loss treatments. We help those who may need specialised support and will aim to make your journey of using GLP-1s as straightforward as possible.

If you need a weight loss journey that is not a quick sign-off online, then contact our team today at the Bodyline Clinic.

About The Author

Sally-Anne Turner

I am founder and Managing Director of Bodyline, with over two decades of experience in the healthcare and wellness industries. I combine a deep understanding of medical wellness with a passion for science-backed health solutions and future-focused care. I have a specialist interest in developing gold standard clinical services for medical weight loss, including the latest GLP-1 medications, hormone health, and low-dose naltrexone (LDN) treatments.

Related Treatment News